MX2019013621A - Agonistas del receptor de interleuquina-15 de accion prolongada y composiciones y metodos inmunoterapeuticos relacionados. - Google Patents
Agonistas del receptor de interleuquina-15 de accion prolongada y composiciones y metodos inmunoterapeuticos relacionados.Info
- Publication number
- MX2019013621A MX2019013621A MX2019013621A MX2019013621A MX2019013621A MX 2019013621 A MX2019013621 A MX 2019013621A MX 2019013621 A MX2019013621 A MX 2019013621A MX 2019013621 A MX2019013621 A MX 2019013621A MX 2019013621 A MX2019013621 A MX 2019013621A
- Authority
- MX
- Mexico
- Prior art keywords
- acting
- long
- interleuquin
- related compositions
- receptor agonists
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000000018 receptor agonist Substances 0.000 title abstract 2
- 229940044601 receptor agonist Drugs 0.000 title abstract 2
- 230000001024 immunotherapeutic effect Effects 0.000 title 1
- 102000004556 Interleukin-15 Receptors Human genes 0.000 abstract 1
- 108010017535 Interleukin-15 Receptors Proteins 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 230000005965 immune activity Effects 0.000 abstract 1
- 230000002459 sustained effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2086—IL-13 to IL-16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7156—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interferons [IFN]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762506494P | 2017-05-15 | 2017-05-15 | |
| US201762536966P | 2017-07-25 | 2017-07-25 | |
| US201762582186P | 2017-11-06 | 2017-11-06 | |
| US201862648240P | 2018-03-26 | 2018-03-26 | |
| PCT/US2018/032817 WO2018213341A1 (en) | 2017-05-15 | 2018-05-15 | Long-acting interleukin-15 receptor agonists and related immunotherapeutic compositions and methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019013621A true MX2019013621A (es) | 2020-01-13 |
Family
ID=64274790
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019013621A MX2019013621A (es) | 2017-05-15 | 2018-05-15 | Agonistas del receptor de interleuquina-15 de accion prolongada y composiciones y metodos inmunoterapeuticos relacionados. |
| MX2024009988A MX2024009988A (es) | 2017-05-15 | 2019-11-14 | Agonistas del receptor de interleuquina-15 de accion prolongada y composiciones y metodos inmunoterapeuticos relacionados. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024009988A MX2024009988A (es) | 2017-05-15 | 2019-11-14 | Agonistas del receptor de interleuquina-15 de accion prolongada y composiciones y metodos inmunoterapeuticos relacionados. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US12036283B2 (enExample) |
| EP (1) | EP3624827A4 (enExample) |
| JP (3) | JP7316222B2 (enExample) |
| KR (2) | KR20250057110A (enExample) |
| CN (2) | CN119700941A (enExample) |
| AU (2) | AU2018270926C1 (enExample) |
| CA (1) | CA3060410A1 (enExample) |
| IL (2) | IL318018A (enExample) |
| MX (2) | MX2019013621A (enExample) |
| WO (1) | WO2018213341A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019222296A1 (en) | 2018-05-14 | 2019-11-21 | Werewolf Therapeutics, Inc. | Activatable interleukin 12 polypeptides and methods of use thereof |
| MX2020012251A (es) | 2018-05-14 | 2021-04-28 | Werewolf Therapeutics Inc | Polipeptidos de interleucina-2 activables y metodos de uso de los mismos. |
| JP7611136B2 (ja) * | 2018-11-09 | 2025-01-09 | ネクター セラピューティクス | 別の薬理学的に活性な薬剤と組み合わせた長時間作用型インターロイキン－１５受容体作動薬 |
| IL286971B1 (en) * | 2019-04-05 | 2026-08-01 | Nektar Therapeutics | Long-acting interleukin-15 receptor agonist in combination with chimeric antigen receptor (CAR-T) cells |
| BR112021022666A2 (pt) | 2019-05-14 | 2022-03-29 | Werewolf Therapeutics Inc | Frações de separação e seus métodos e uso |
| SG11202111409YA (en) | 2019-05-20 | 2021-12-30 | Cytune Pharma | IL-2/IL-15Rßy AGONIST DOSING REGIMENS FOR TREATING CANCER OR INFECTIOUS DISEASES |
| BR112022009110A2 (pt) | 2019-11-14 | 2022-07-26 | Werewolf Therapeutics Inc | Polipeptídeos de citocina ativáveis e métodos de uso destes |
| WO2022090203A1 (en) | 2020-10-26 | 2022-05-05 | Cytune Pharma | IL-2/IL-15Rβү AGONIST FOR TREATING SQUAMOUS CELL CARCINOMA |
| KR20230096047A (ko) | 2020-10-26 | 2023-06-29 | 싸이튠 파마 | 비흑색종 피부암 치료용 IL-2/IL-15Rβγ 작용제 |
| JP2024526080A (ja) | 2021-06-23 | 2024-07-17 | サイチューン ファーマ | インターロイキン１５多様体 |
| US20240350589A1 (en) | 2021-08-13 | 2024-10-24 | Cytune Pharma | Il-2/il-15rbetagamma agonist combination with antibody-drug conjugates for treating cancer |
| WO2024173571A1 (en) * | 2023-02-14 | 2024-08-22 | Amcyte Pharma, Inc. | Interleukin formulations for in vivo use |
| EP4694916A1 (en) | 2023-04-14 | 2026-02-18 | SOTIO Biotech Inc. | Engineered immune cells for treating cancer in combination with il-2/il-15 receptor ?? agonists |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5166322A (en) | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
| US5446090A (en) | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
| US6110721A (en) | 1993-11-12 | 2000-08-29 | Gilead Sciences, Inc. | Polypeptides and coagulation therapy |
| WO1995027722A1 (en) | 1994-04-06 | 1995-10-19 | Immunex Corporation | Interleukin-15 |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| US5795966A (en) | 1995-02-22 | 1998-08-18 | Immunex Corp | Antagonists of interleukin-15 |
| US7008624B1 (en) | 1995-02-22 | 2006-03-07 | Immunex Corporation | Antagonists of interleukin-15 |
| CA2323048C (en) | 1998-03-12 | 2006-10-10 | Shearwater Polymers, Inc. | Poly(ethylene glycol) derivatives with proximal reactive groups |
| US6602498B2 (en) | 2000-02-22 | 2003-08-05 | Shearwater Corporation | N-maleimidyl polymer derivatives |
| RS20050501A (sr) | 2002-12-26 | 2007-08-03 | Mountain View Pharmaceuticals Inc., | Polimerni konjugati citokina,hemokina,faktora rasta, polipeptidnih hormona i njihovih antagonista sa očuvanom aktivnošću vezivanja receptora |
| ATE444984T1 (de) | 2002-12-31 | 2009-10-15 | Nektar Therapeutics Al Corp | Hydrolysestabile maleimidendgruppen-enthaltende polymere |
| US7910661B2 (en) | 2003-01-06 | 2011-03-22 | Nektar Therapeutics | Thiol-selective water-soluble polymer derivatives |
| US7276478B2 (en) | 2003-09-25 | 2007-10-02 | Zymogenetics, Inc. | Methods of treating autoimmune diseases using IL-21 |
| US20060057680A1 (en) | 2004-08-11 | 2006-03-16 | Zheng Xin X | Mutant interleukin-15 polypeptides |
| US20060104945A1 (en) | 2004-10-05 | 2006-05-18 | Choi Yong S | Enhancement of B cell proliferation by IL-15 |
| US20060257361A1 (en) | 2005-04-12 | 2006-11-16 | Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services | Novel form of interleukin-15, Fc-IL-15, and methods of use |
| CA2611823C (en) | 2005-06-16 | 2013-07-30 | Nektar Therapeutics Al, Corporation | Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates |
| CN106046370A (zh) | 2007-02-28 | 2016-10-26 | 塞瑞纳治疗公司 | 聚噁唑啉poz化合物、合成其的方法、以及靶分子‑poz偶联物 |
| LT2237799T (lt) | 2008-02-01 | 2019-07-25 | Ascendis Pharma A/S | Provaistas, apimantis besiskaidantį linkerį |
| EP2350118B1 (en) * | 2008-09-19 | 2016-03-30 | Nektar Therapeutics | Carbohydrate-based drug delivery polymers and conjugates thereof |
| JP5775820B2 (ja) | 2008-10-21 | 2015-09-09 | バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ | 遊離可能ｐｅｇ試薬を有するプロドラッグｐｅｇタンパク質結合体において活性成分（インビトロ脱ペグ化）を決定する方法 |
| TWI534152B (zh) | 2010-07-30 | 2016-05-21 | 巴克斯特國際公司 | 用於肟連接的親核性催化劑 |
| ES2866674T3 (es) | 2010-11-12 | 2021-10-19 | Nektar Therapeutics | Conjugados de una fracción de IL-2 y un polímero |
| CN102145178B (zh) * | 2011-04-15 | 2012-09-26 | 北京凯因科技股份有限公司 | Peg化白介素15 |
| WO2013020079A2 (en) | 2011-08-04 | 2013-02-07 | Nektar Therapeutics | Conjugates of an il-11 moiety and a polymer |
| WO2014201378A1 (en) | 2013-06-13 | 2014-12-18 | Massachusetts Institute Of Technology | Synergistic tumor treatment with extended-pk il -2 and adoptive cell therapy |
| MA39711A (fr) * | 2014-04-03 | 2015-10-08 | Nektar Therapeutics | Conjugués d'une fraction d'il-15 et d'un polymère |
| EP3206713A4 (en) * | 2014-10-14 | 2018-06-27 | Armo Biosciences, Inc. | Interleukin-15 compositions and uses thereof |
| WO2017062832A1 (en) * | 2015-10-08 | 2017-04-13 | Nektar Therapeutics | Combination of an il-2rbeta-selective agonist and a long-acting il-15 agonist |
-
2018
- 2018-05-15 KR KR1020257012326A patent/KR20250057110A/ko active Pending
- 2018-05-15 EP EP18803095.1A patent/EP3624827A4/en active Pending
- 2018-05-15 IL IL318018A patent/IL318018A/en unknown
- 2018-05-15 MX MX2019013621A patent/MX2019013621A/es unknown
- 2018-05-15 CA CA3060410A patent/CA3060410A1/en active Pending
- 2018-05-15 US US16/613,757 patent/US12036283B2/en active Active
- 2018-05-15 JP JP2019563255A patent/JP7316222B2/ja active Active
- 2018-05-15 AU AU2018270926A patent/AU2018270926C1/en active Active
- 2018-05-15 IL IL270634A patent/IL270634B2/en unknown
- 2018-05-15 KR KR1020197036787A patent/KR102798243B1/ko active Active
- 2018-05-15 CN CN202411943619.6A patent/CN119700941A/zh active Pending
- 2018-05-15 WO PCT/US2018/032817 patent/WO2018213341A1/en not_active Ceased
- 2018-05-15 CN CN201880032373.3A patent/CN111093688B/zh active Active
-
2019
- 2019-11-14 MX MX2024009988A patent/MX2024009988A/es unknown
-
2022
- 2022-05-31 AU AU2022203691A patent/AU2022203691B2/en active Active
-
2023
- 2023-04-10 JP JP2023063333A patent/JP7772733B2/ja active Active
-
2024
- 2024-06-06 US US18/735,818 patent/US20240424115A1/en active Pending
-
2025
- 2025-05-01 JP JP2025076268A patent/JP2025111770A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL270634A (en) | 2019-12-31 |
| KR20250057110A (ko) | 2025-04-28 |
| CN119700941A (zh) | 2025-03-28 |
| AU2022203691B2 (en) | 2023-10-12 |
| KR20200003922A (ko) | 2020-01-10 |
| WO2018213341A1 (en) | 2018-11-22 |
| JP2025111770A (ja) | 2025-07-30 |
| IL318018A (en) | 2025-02-01 |
| IL270634B2 (en) | 2025-06-01 |
| JP2023082218A (ja) | 2023-06-13 |
| JP7772733B2 (ja) | 2025-11-18 |
| EP3624827A4 (en) | 2021-03-03 |
| IL270634B1 (en) | 2025-02-01 |
| AU2018270926C1 (en) | 2022-10-27 |
| AU2022203691A1 (en) | 2022-06-16 |
| JP7316222B2 (ja) | 2023-07-27 |
| CA3060410A1 (en) | 2018-11-22 |
| EP3624827A1 (en) | 2020-03-25 |
| JP2020519676A (ja) | 2020-07-02 |
| KR102798243B1 (ko) | 2025-04-18 |
| US20240424115A1 (en) | 2024-12-26 |
| US12036283B2 (en) | 2024-07-16 |
| US20200078467A1 (en) | 2020-03-12 |
| MX2024009988A (es) | 2024-08-27 |
| AU2018270926B2 (en) | 2022-04-07 |
| AU2018270926A1 (en) | 2019-11-07 |
| CN111093688A (zh) | 2020-05-01 |
| CN111093688B (zh) | 2025-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024009988A (es) | Agonistas del receptor de interleuquina-15 de accion prolongada y composiciones y metodos inmunoterapeuticos relacionados. | |
| AR131056A2 (es) | Composiciones para tratar un trastorno hipofosfatémico | |
| PH12016501966B1 (en) | Compounds and compositions as toll-like receptor 7 agonists | |
| ECSP17021754A (es) | Composiciones y métodos de uso para tratar trastornos metabólicos | |
| NZ724878A (en) | Compounds and compositions as toll-like receptor 7 agonists | |
| ECSP18094857A (es) | Agonista del receptor de glucocorticoides e inmunoconjugados del mismo | |
| ECSP17005276A (es) | Composiciones y métodos de uso para tratar trastornos metabólicos | |
| MX389560B (es) | Enfoque de inmunoterapias de combinación para el tratamiento del cancer. | |
| AR102712A1 (es) | Agonistas parciales del receptor de insulina | |
| MX2016007972A (es) | Metodos para tratar canceres con antagonistas de union al eje pd-1 y taxanos. | |
| CL2015002640A1 (es) | Agentes inductores de la apoptosis para tratar el cáncer y enfermedades inmunes y autoinmunes | |
| MX2018005544A (es) | Uso de agonistas del receptor tipo toll- 8 (tlr8) para tratar cancer. | |
| MX2018003388A (es) | Agonistas del receptor farnesoide x y usos de los mismos. | |
| CL2016003422A1 (es) | Inhibidores de demetilasa-1 específico de lisina | |
| MX2019012938A (es) | Uso del inhibidor mejorador de homologo zeste 2 (ezh2) combinado con el inhibidor tirosina cinasa de bruton (btk) en la preparacion de farmacos para tratar tumores. | |
| CL2016000436A1 (es) | Método para el tratamiento de la enfermedad fibrótica | |
| MX388845B (es) | Uso de pridopidina para tratar el sindrome de rett. | |
| MX374385B (es) | Apilimod para uso en el tratamiento de melanoma. | |
| MX2020004411A (es) | Anticuerpos anti-cd40 para usarse en el tratamiento del sindrome de sjogren. | |
| BR112017002354A2 (pt) | artigo absorvente extensível | |
| MX2017001632A (es) | Mioinositol y probioticos, y uso de estos. | |
| PH12016501434A1 (en) | Compositions for use in the treatment of allergic conditions | |
| UY35823A (es) | Profármacos de antagonista de nmda | |
| TWD175950S (zh) | 椅背腰靠框 | |
| AR105728A1 (es) | Lisobactina para su uso en el tratamiento de la mastitis bovina |